Translational immunotoxicology of immunomodulatory monoclonal antibodies

Frank R Brennan1, Andrea Kiessling1

  • 1UCB Pharma, 208 Bath Road, Slough SL1 3WE, UK.

While immunomodulatory monoclonal antibodies (mAbs) have a wide therapeutic potential, exaggerated immunopharmacology may drive both acute and delayed immunotoxicity. The existing tools for immunotoxicity assessment do not accurately predict the full range of immunotoxicities observed in humans. New and optimized models, assays, endpoints and biomarkers in animals and humans are required to safeguard patients and allow them access to these often transformational therapies.